DBR1 as A Drug Target for DR: Unlocking The Potential of Antibiotics

Target Name: DBR1

NCBI ID: G51163

DBR1

DBR1 as A Drug Target for DR: Unlocking The Potential of Antibiotics

Drug resistance (DR) is a major clinical problem that has a significant impact on patient outcomes. DR is caused by the evolution of bacteria, viruses, and other microorganisms that have the ability to resist the effects of antibiotics. This evolution can occur through a variety of mechanisms, including the acquisition of mutations that confer resistance, the development of antibiotic resistance gene (ARG) families, and the formation of multi-resistant strains.

DBR1, a gene that encodes a protein involved in the detoxification of xenobiotics, has been identified as a potential drug target for DR. The DBR1 gene is located on chromosome 18 and encodes a protein with 21 kDa. The protein is expressed in many different tissues and organs, including the liver, spleen, kidney, and intestine.

Function and localization

The DBR1 protein is involved in the detoxification of a wide variety of xenobiotics, including drugs like tetracycline, amoxicillin, and ertapenem. It is also involved in the detoxification of certain metabolites of drugs, such as warfarin.

The DBR1 gene is located on chromosome 18, specifically on the q region. It is transcribed into a gene that encodes a protein with 21 kDa. The protein is located in the cytoplasm and is involved in the detoxification of a wide variety of xenobiotics.

Drug resistance

DBR1 has been shown to be involved in drug resistance. Studies have shown that the DBR1 gene is associated with the development of drug resistance in bacteria, including antibiotic-resistant Staphylococcus aureus (S. aureus) and antibiotic-resistant Pseudomonas aeruginosa (P. aeruginosa ).

In addition, the DBR1 gene has also been shown to be involved in the development of resistance to other classes of antibiotics, such as 尾-lactams and fluoroquinones. This suggests that DBR1 may be a useful target for the development of new antibiotics.

Antibiotic use

Antibiotic use is a common practice for treating bacterial and other infections. However, antibiotic resistance is a major problem that can reduce the effectiveness of these treatments. The development of antibiotic resistance can occur through a variety of mechanisms, including the acquisition of mutations that confer resistance, the development of antibiotic resistance gene (ARG) families, and the formation of multi-resistant strains.

The DBR1 gene has the potential to be a drug target for DR because it is involved in the detoxification of xenobiotics, which are often used as antibiotics. The DBR1 gene may be a useful target for the development of new antibiotics that are effective against antibiotic- resistant organisms.

Conclusion

DBR1 is a gene that encodes a protein involved in the detoxification of xenobiotics. The DBR1 gene is located on chromosome 18 and has been shown to be involved in the development of drug resistance in bacteria. The potential use of DBR1 as a drug target for DR is an exciting area of 鈥嬧?媟esearch that may lead to new and effective treatments for bacterial and other infections.

Protein Name: Debranching RNA Lariats 1

Functions: Cleaves the 2'-5' phosphodiester linkage at the branch point of excised lariat intron RNA and converts them into linear molecules that can be subsequently degraded, thereby facilitating ribonucleotide turnover (PubMed:10982890, PubMed:2435736, PubMed:16232320). Linked to its role in pre-mRNA processing mechanism, may also participate in retrovirus replication via an RNA lariat intermediate in cDNA synthesis and have an antiviral cell-intrinsic defense function in the brainstem (PubMed:16232320, PubMed:29474921)

The "DBR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DBR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets